Asia · Regional markets · The Financial Express
Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028
Detailed summary
Biocon wins US FDA approval for cancer biosimilar Pebrilzo, strengthening its oncology portfolio ahead of a 2028 launch; learn more.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.financialexpress.com)



